michael s
(Michael S)
#1
63 What drugs should be used to maintain
someone in sinus rhythm who has paroxysmal
atrial fibrillation? Is there a role for digoxin?
Suzanna Hardman and Martin Cowie
The natural history of patients with paroxysmal atrial fibrillation
is that over a period of time (and often many years) there is a
gradual tendency to an increased frequency and duration of
attacks. A proportion of patients will develop chronic atrial
fibrillation. Not all patients require antiarrhythmic drugs and the
potential side effects and inconvenience of regular medication
must be balanced against the frequency of episodes and
symptomatology which vary markedly between patients.
Triggers include alcohol and caffeine, ischaemia, untreated
hypertension (which if aggressively managed can at least in the
short term obviate the need for antiarrhythmics), thyrotoxicosis,
and in a small proportion of patients vagal or sympathetic stimu-
lation where attacks are typically preceded by a drop in heart rate
or exercise respectively.
The most effective drugs are also those with potentially
dangerous side effects. The risks of class 1 agents (such as
flecainide, disopyramide and propafenone) in patients with
underlying coronary artery disease are well recognised and are
best avoided. In younger patients (where it is presumed the
associated risks are proportionately less) they can be highly
effective. Sotalol may be useful in some patients but adequate
dosing is required to achieve class 3 antiarrhythmic activity and
not all patients will tolerate the associated degree of beta
blockade. Amiodarone can be highly effective but its use is
limited by the incidence of serious side effects. Beta blockers and
calcium channel blockers have no role in preventing paroxysms
of atrial fibrillation but can help certain patients in reducing the
rate and so symptomatology.
Despite the long-standing conviction of many clinicians that
digoxin is efficacious in the management of paroxysmal atrial
fibrillation it has been clearly shown that digoxin neither reduces
the frequency of attacks nor produces any useful reduction of
heart rate during paroxysms of atrial fibrillation. Furthermore a
number of placebo-controlled studies designed to explore the
possibility that digoxin might chemically cardiovert patients